127
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Comorbidity Associations with AATD Among Commercially Insured and Medicare Beneficiaries with COPD in the US

ORCID Icon, ORCID Icon, ORCID Icon, , &
Pages 2389-2397 | Published online: 05 Oct 2020

References

  • LarssonC. Natural history and life expectancy in severe α-1 antitrypsin deficiency, PiZ. Acta Med Scand. 1978;204:345–351. doi:10.1111/j.0954-6820.1978.tb08452.x309708
  • SvegerT. Liver disease in α-1 antitrypsin deficiency detected by screening of 200,000 infants. N Eng J Med. 1976;294:1316–1321. doi:10.1056/NEJM197606102942404
  • ErikssonS, CarisonJ, VelezR. Risks for cirrhosis and primary liver cancer in α-1 antitrypsin deficiency. N Eng J Med. 1986;314:736–739. doi:10.1056/NEJM198603203141202
  • O’RiordanK, BleiA, RaoMS, et al. α-1-antitrypsin deficiency-associated panniculitis. Transplantation. 1997;53:480–482. doi:10.1097/00007890-199702150-00028
  • EsnaultVLM, TestaA, AudrainM, et al. Alpha1-antitrypsin genetic polymorphism in ANCA-positive systemic vasculitis. Kidney Int. 1993;43:1329–1332. doi:10.1038/ki.1993.1868315946
  • ElzoukiANY, SegelmarkM, WieslanderJ, et al. Strong link between the alpha1-antitrypsin PiZ allele and Wegener’s granulomatosis. J Intern Med. 1994;236:543–548. doi:10.1111/j.1365-2796.1994.tb00842.x7964431
  • BrantlyM, NukiwaT, CrystalRG. Molecular basis of alpha-1-antitrypsin deficiency. Am J Med. 1988;84(6A):13–31. doi:10.1016/0002-9343(88)90154-43289385
  • BrantlyML. Efficient and accurate approaches to the laboratory diagnosis of α1-antitrypsin deficiency: the promise of early diagnosis and intervention. Clin Chem. 2006;52:2180–2181. doi:10.1373/clinchem.2006.07890717138849
  • CrystalRG. α1-antitrypsin deficiency, emphysema, and liver disease: genetic basis and strategies for therapy. J Clin Invest. 1990;85:1343–1352. doi:10.1172/JCI1145782185272
  • O’BrienML, BuistNR, MurphyWH. Neonatal screening for alpha-1 antitrypsin deficiency. J Pediatr. 1978;92:1006–1010. doi:10.1016/S0022-3476(78)80388-6307054
  • SilvermanEK, MiletickJP, PierceJA, et al. Alpha-1-antitrypsin deficiency: high prevalence in the St. Louis area determined by direct population screening. Am Rev Respir Dis. 1989;140(4):961–966. doi:10.1164/ajrccm/140.4.9612679271
  • LiebermanJ, WinterB, SastreA. Alpha-1 antitrypsin Pi-types 965 COPD patients. Chest. 1986;89:370–373. doi:10.1378/chest.89.3.3703485034
  • RahaghiFF, SandhausRA, BrantlyML, et al. The prevalence of alpha-1 antitrypsin deficiency among patients found to have airflow obstruction. COPD. 2012;9(4):352–358. doi:10.3109/15412555.2012.66943322506682
  • de SerresFJ, BlancoI, Fernandez-BustilloE. Genetic epidemiology of alpha-1 antitrypsin deficiency in North America and Australia/New Zealand: Australia, Canada, New Zealand and the United States of America. Clin Genet. 2003;64:382–397. doi:10.1034/j.1399-0004.2003.00143.x14616761
  • SandhausRA, TurinoG, BrantlyML, et al. Clinical practice guidelines: the diagnosis and management of alpha-1 antitrypsin deficiency in the adult. Chronic Obstr Pulm Dis. 2016;3(3):668–682.28848891
  • StollerJK, AboussouanLS. Alpha-1 antitrypsin deficiency. Lancet. 2005;365:2225–2236. doi:10.1016/S0140-6736(05)66781-515978931
  • MayerAS, StollerJK, Bucher BartelsonB, et al. Occupational exposure risks in individuals with PI*Z α1-antitrypsin deficiency. Am J Respir Crit Care Med. 2000;162:553–588. doi:10.1164/ajrccm.162.2.990711710934086
  • American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168(7):818–900.14522813
  • StollerJK, SmithP, YangP, et al. Physical and social impact of alpha-1 antitrypsin deficiency: results of a survey. Cleve Clin J Med. 1994;61:461–467. doi:10.3949/ccjm.61.6.4617828337
  • CamposMA, WannerA, ZhangG, et al. Trends in the diagnosis of symptomatic patients with alpha-1 antitrypsin deficiency between 1968 and 2003. Chest. 2005;128(3):1179–1186. doi:10.1378/chest.128.3.117916162704
  • StollerJK, SandhausRA, TurinoG, et al. Delay in diagnosis of α1-antitrypsin deficiency. Chest. 2005;128:1989–1994. doi:10.1378/chest.128.4.198916236846
  • KohnleinT, JanciauskieneS, WelteT. Diagnostic delay and clinical modifiers in alpha-1 antitrypsin deficiency. Ther Adv Respir Dis. 2010;4(5):279. doi:10.1177/175346581037640720660539
  • GreulichT, VogelmeierCF. Alpha-1-antitrypsin deficiency: increasing awareness and improving diagnosis. Ther Adv Respir Dis. 2016;10(1):72–84. doi:10.1177/175346581560216226341117
  • McElvaneyNG, StollerJK, BuistAS, et al. Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of alpha 1-antitrypsin deficiency. Alpha 1-Antitrypsin Deficiency Registry Study Group. Chest. 1997;111(2):394–403. doi:10.1378/chest.111.2.3949041988
  • StollerJK, AboussouanLS, KannerRE, et al. Characteristics of alpha-1 antitrypsin-deficient individuals in the long-term oxygen treatment trial and comparison with other subjects with chronic obstructive pulmonary disease. Annals ATS. 2015;12(12):1796–1804. doi:10.1513/AnnalsATS.201506-389OC
  • ParrDG, StoelBC, StolkJ, et al. Pattern of emphysema distribution in α1-antitrypsin deficiency influences lung function impairment. Am J Respir Crit Care Med. 2004;170:1172–1178. doi:10.1164/rccm.200406-761OC15306534
  • CarpenterMJ, StrangeC, JonesY, et al. Does genetic testing result in behavioral health change? Changes in smoking behavior following testing for alpha-1 antitrypsin deficiency. Ann Behav Med. 2007;33(1):22–28. doi:10.1207/s15324796abm3301_317291167
  • FFS Data (2008-2016). Available from: https://www.cms.gov/Medicare/Health-Plans/MedicareAdvtgSpecRateStats/FFS-Data.html. Accessed 124, 2019.
  • IQVIA. Available from: https://www.iqvia.com/institute/research-support. Accessed 124, 2019..
  • ElixhauserA, SteinerC, HarrisDR, et al. Comorbidity measures for use with administrative data. Med Care. 1998;36:8–27. doi:10.1097/00005650-199801000-000049431328
  • MorganAD, ZakeriR, QuintJK. Defining the relationship between COPD and CVD: what are the implications for clinical practice? Ther Adv Respir Dis. 2018;12:1–16. doi:10.1177/1753465817750524
  • DivoM, CoteC, de TorresJP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(2):155–161. doi:10.1164/rccm.201201-0034OC22561964
  • GershonAS, MecredyGC, GuanJ, et al. Quantifying comorbidity in individuals with COPD: a population study. Eur Respir J. 2015;45:51–59. doi:10.1183/09031936.0006141425142481
  • ChenW, ThomasJ, SadatsafaviM, et al. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(8):631–639. doi:10.1016/S2213-2600(15)00241-626208998
  • DivoMJ, CelliBR, Poblador-PlouB, et al. Chronic obstructive pulmonary disease (COPD) as a disease of early aging: evidence from the EpiChron cohort. PLoS One. 2018;13(2):e0193143. doi:10.1371/journal.pone.019314329470502
  • AhlgrenAR, PiitulainenE, SonesssonB, et al. Changes in aortic wall stiffness in men with α1-antitrypsin deficiency. Eur J Vasc Endovasc Surg. 1997;14:252–257. doi:10.1016/S1078-5884(97)80236-59366788
  • DuckersJM, ShaleDJ, StockleyRA, et al. Cardiovascular and musculoskeletal co-morbidities in patients with alpha 1 antitrypsin deficiency. Respir Res. 2010;11:173. doi:10.1186/1465-9921-11-17321138571
  • KumbhareS, HuntKJ, NietertPJ, et al. Hypertension prevalence in the US population varies with differences in alpha-1 antitrypsin genotype: a cross sectional study. Br J Med Res. 2015;5(7):880–888. doi:10.9734/BJMMR/2015/13447
  • DahlM, Tybjaerg-HansenA, NordestgaardBG. Risk of ischemic heart and ischemic cerebrovascular disease in not increased in S, Z, and 11478A α1-antitrypsin carriers of the Copenhagen City Heart Study. Arterioscler Thromb Vasc Biol. 2003;23(11):55. doi:10.1161/01.ATV.0000097980.11819.93
  • BoomsmaDI, OrbelekeJF, MartinNG, et al. Alpha-1-antitrypsin and blood pressure. Lancet. 1991;337(8756):1547. doi:10.1016/0140-6736(91)93238-5
  • HuggardPR, WestMJ, SummersKM. Alpha 1-antitrypsin deficiency alleles and blood pressure in an Australian population. Clin Exp Pharmacol Physiol. 1996;23(6–7):600–601. doi:10.1111/j.1440-1681.1996.tb02792.x8800597
  • FähndrichS, BiertzF, KarchA, et al. Cardiovascular risk in patients with alpha-1-antitrypsin deficiency. Respir Res. 2017;18:171. doi:10.1186/s12931-017-0655-128915894
  • LyonsPA, RaynerTF, TrivediS, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Eng J Med. 2012;367(3):214–223. doi:10.1056/NEJMoa1108735
  • BeckmanG, BeckmanL, BielleA, et al. Alpha-1-antitrypsin types and rheumatoid arthritis. Clin Genet. 1984;25(6):496–499. doi:10.1111/j.1399-0004.1984.tb00493.x6610507
  • YangP, TremaineWJ, MeyerRI, et al. Alpha1-antitrypsin deficiency and inflammatory bowel diseases. Mayo Clin Proc. 2000;75(5):450–455. doi:10.1016/S0025-6196(11)64212-210807072
  • GreulichT, NellC, HohmannD, et al. The prevalence of diagnosed α1-antitrypsin deficiency and its comorbidities: results from a large population-based database. Eur Respir J. 2017;49:1600154. doi:10.1183/13993003.00154-201627824593